127 related articles for article (PubMed ID: 38599922)
21. Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis.
Costa S; Mondini M; Caneparo V; Afeltra A; Airò P; Bellisai F; Faggioli P; Gerli R; Lotzniker M; Meroni PL; Morozzi G; Radice A; Riccieri V; Scarsi M; Sebastiani GD; Sinico RA; Tincani A; Gariglio M; Landolfo S
Rheumatology (Oxford); 2011 Apr; 50(4):674-81. PubMed ID: 21134960
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of anti-Ro52-kDa/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: Data from a French cohort, a systematic review and meta-analysis.
Martel ME; Leurs A; Launay D; Behal H; Chepy A; Collet A; Sanges S; Hachulla E; Dubucquoi S; Dauchet L; Sobanski V
Autoimmun Rev; 2024 May; 23(5):103536. PubMed ID: 38555075
[TBL] [Abstract][Full Text] [Related]
23. Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.
Satoh M; Ceribelli A; Hasegawa T; Tanaka S
Clin Rev Allergy Immunol; 2022 Oct; 63(2):210-239. PubMed ID: 35258843
[TBL] [Abstract][Full Text] [Related]
24. Juvenile systemic sclerosis: report of three cases and review of Japanese published work.
Aoyama K; Nagai Y; Endo Y; Ishikawa O
J Dermatol; 2007 Sep; 34(9):658-61. PubMed ID: 17727371
[TBL] [Abstract][Full Text] [Related]
25. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis.
Hesselstrand R; Scheja A; Shen GQ; Wiik A; Akesson A
Rheumatology (Oxford); 2003 Apr; 42(4):534-40. PubMed ID: 12649400
[TBL] [Abstract][Full Text] [Related]
26. Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach.
Van Praet JT; Van Steendam K; Smith V; De Bruyne G; Mimori T; Bonroy C; Elewaut D; Deforce D; De Keyser F
Rheumatology (Oxford); 2011 Jul; 50(7):1302-9. PubMed ID: 21330340
[TBL] [Abstract][Full Text] [Related]
27. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.
Mierau R; Moinzadeh P; Riemekasten G; Melchers I; Meurer M; Reichenberger F; Buslau M; Worm M; Blank N; Hein R; Müller-Ladner U; Kuhn A; Sunderkötter C; Juche A; Pfeiffer C; Fiehn C; Sticherling M; Lehmann P; Stadler R; Schulze-Lohoff E; Seitz C; Foeldvari I; Krieg T; Genth E; Hunzelmann N
Arthritis Res Ther; 2011; 13(5):R172. PubMed ID: 22018289
[TBL] [Abstract][Full Text] [Related]
28. Association between autoantibodies in systemic sclerosis and cancer in a national registry.
Hoa S; Lazizi S; Baron M; Wang M; Fritzler MJ; Hudson M;
Rheumatology (Oxford); 2022 Jul; 61(7):2905-2914. PubMed ID: 34599801
[TBL] [Abstract][Full Text] [Related]
29. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
[TBL] [Abstract][Full Text] [Related]
30. Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?
Benyamine A; Bertin D; Heim X; Granel B; Bardin N
Eur J Intern Med; 2017 Oct; 44():e42-e44. PubMed ID: 28781194
[No Abstract] [Full Text] [Related]
31. Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening.
Lazzaroni MG; Cavazzana I; Colombo E; Dobrota R; Hernandez J; Hesselstrand R; Varju C; Nagy G; Smith V; Caramaschi P; Riccieri V; Hachulla E; Balbir-Gurman A; Chatelus E; Romanowska-Próchnicka K; Araújo AC; Distler O; Allanore Y; Airò P;
J Rheumatol; 2017 May; 44(5):639-647. PubMed ID: 28089973
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A; Huang S; Carreira PE; Siegert E; de Vries-Bouwstra J; Distler JHW; Smith V; Del Galdo F; Anic B; Damjanov N; Rednic S; Ribi C; Bancel DF; Hoffmann-Vold AM; Gabrielli A; Distler O; Khanna D; Allanore Y;
JAMA Dermatol; 2023 Aug; 159(8):837-847. PubMed ID: 37378994
[TBL] [Abstract][Full Text] [Related]
33. The clinical relevance of autoantibodies in scleroderma.
Ho KT; Reveille JD
Arthritis Res Ther; 2003; 5(2):80-93. PubMed ID: 12718748
[TBL] [Abstract][Full Text] [Related]
34. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database.
Schneeberger D; Tyndall A; Kay J; Søndergaard KH; Carreira PE; Morgiel E; Deuschle K; Derk CT; Widuchowska M; Walker UA
Rheumatology (Oxford); 2013 Mar; 52(3):560-7. PubMed ID: 23221323
[TBL] [Abstract][Full Text] [Related]
35. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie).
Tiev KP; Diot E; Clerson P; Dupuis-Siméon F; Hachulla E; Hatron PY; Constans J; Cirstéa D; Farge-Bancel D; Carpentier PH
J Rheumatol; 2009 Jul; 36(7):1470-6. PubMed ID: 19487271
[TBL] [Abstract][Full Text] [Related]
36. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies.
Airo' P; Ceribelli A; Cavazzana I; Taraborelli M; Zingarelli S; Franceschini F
J Rheumatol; 2011 Jul; 38(7):1329-34. PubMed ID: 21459934
[TBL] [Abstract][Full Text] [Related]
37. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
38. Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting.
Kuwana M
J Nippon Med Sch; 2017; 84(2):56-63. PubMed ID: 28502960
[TBL] [Abstract][Full Text] [Related]
39. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Ceribelli A; Krzyszczak ME; Li Y; Ross SJ; Chan JY; Chan EK; Burlingame RW; Webb TT; Bubb MR; Sobel ES; Reeves WH; Satoh M
Arthritis Res Ther; 2011 Jul; 13(4):R119. PubMed ID: 21781293
[TBL] [Abstract][Full Text] [Related]
40. [Autoantibodies in systemic sclerosis: clinical interest and diagnosis approach].
Admou B; Essaadouni L; Amal S; Arji N; Chabaa L; El Aouad R
Ann Biol Clin (Paris); 2009; 67(3):273-81. PubMed ID: 19411229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
